Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel vs. Bupivacaine for TAP Blocks in Hernia Repair
NCT03541941Phase 4Completed
- Sponsor
- Cleveland Clinic
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in postoperative pain (3 arms), sponsored by Cleveland Clinic. Primary endpoints: Cumulative Opioid Requirements for 72 Hours After Surgery and Cumulative Opioid Requirements at Postoperative Days 0, 1, 2, 3. Started Jul 2018; status: completed.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03541941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541941.